Cencora, Inc. reported revenue of $84.75B for the period ended 2026-06-30, +5.1% year on year. Net income was $0.76B, a 0.9% net margin on a 4.3% gross margin. The largest revenue line is USHealthcare Solutions at 88% of the total. Free cash flow for the period was $2.43B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | $84.75B | +5.1% |
| Gross profit | $3.61B | — |
| Operating income | $1.12B | — |
| Net income | $0.76B | +11.1% |
| Gross margin | 4.3% | Net margin 0.9% |
| Revenue Q/Q | +8.2% | — |
| Segment | Revenue | Share |
|---|---|---|
| USHealthcare Solutions | $74.86B | 88.3% |
| International Healthcare Solutions | $7.68B | 9.1% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | $81.15B | 95.7% |
| SG&A | $2.13B | 2.5% |
| Tax & other | $0.36B | 0.4% |
| Item | Amount |
|---|---|
| Total assets | $83.81B |
| Total liabilities | $80.57B |
| Shareholders' equity | $3.24B |
| Equity / assets | 3.9% |
| Operating cash flow | $2.65B |
| Capital expenditure | $0.23B |
| Free cash flow | $2.43B |
| Cash conversion (OCF / net income) | 348% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
CNC ・ CNP ・ CF ・ CRL ・ SCHW ・ CHTR ・ CVX ・ CMG ・ CB ・ CHD ・ CIEN ・ CI
Source: SEC EDGAR · This page shows public filing data only, not investment advice. · Browse all companies